BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.

In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.

Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.

Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.

Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) – more than any of its other drugs.

At the end of 2023, the company had a m

See Full Page